Related Experiment Video
Updated: May 12, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Predictive biomarkers for bevacizumab: are we there yet?
Dipen Maru1, Alan P Venook, Lee M Ellis
1Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA.
Summary
Identifying predictive biomarkers for vascular endothelial growth factor (VEGF) targeted therapies is crucial. New research suggests circulating VEGF and tumor neuropilin-1 may predict bevacizumab efficacy in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Vascular Endothelial Growth Factor (VEGF) targeted therapies are standard in several solid tumors.
- Previous attempts to find predictive markers for VEGF therapy efficacy were unsuccessful.
- The FDA's withdrawal of bevacizumab for metastatic breast cancer highlights the need for predictive biomarkers.
Discussion:
- Circulating VEGF levels and tumor neuropilin-1 expression were identified as potential predictive biomarkers for bevacizumab in a recent study.
- These markers may help oncologists personalize VEGF-targeted therapy decisions.
- Critical evaluation of these potential biomarkers is necessary.
Key Insights:
- Circulating VEGF and tumor neuropilin-1 expression show promise as predictive biomarkers for bevacizumab.
- Accurate patient selection for VEGF-targeted therapies remains a challenge.
- Biomarker validation is essential for clinical application.
Outlook:
- Further validation of circulating VEGF and tumor neuropilin-1 in prospective clinical trials is required.
- Development of reliable predictive biomarkers will optimize VEGF-targeted therapy use.
- Personalized medicine approaches in oncology are advancing through biomarker research.
